risk factor (mean score 2.2 AE 1.2 with 90% hypertension and 43% $75 years of age). The Watchman was successfully implanted in 88% of patients, and LAAC efficacy was 86% at 45 days and 92% at 6 months.
27% of warfarin patients interrupted warfarin during follow-up (8) . In both groups, all patients with ischemic strokes who had international normalized ratio measured at the time of their ischemic event were subtherapeutic or not taking warfarin (7) . Based on these results, concerns about the risk factor profiles of enrolled patients, confounding by chronic antiplatelet therapy, and poor compliance with protocol mandated anticoagulation strategies (8) , the Watchman device was not approved by the U.S. (50% paroxysmal, 16% permanent) with higher CHADS 2 score (mean 2.6 AE 1.0; 91% hypertension, 54% $75 years of age), used the same Watchman device and anticoagulation protocol as in the PROTECT AF trial, excluded patients on chronic clopidogrel therapy, and followed patients for a mean of 12 months. Notably, to improve the power of the PREVAIL study, some data from the PROTECT AF trial was included in the PREVAIL analysis using a Bayesian informative prior analysis. In the PREVAIL trial, procedure-related adverse events improved to 2.2% and successful device implantation increased to 95% with LAAC efficacy of 92% at 45 days and 98% at 6 months. The Watchman failed to demonstrate noninferiority to long-term warfarin for the composite coprimary endpoint of stroke, systemic embolism, and cardiovascular or unexplained death. In the Watchman group, however, at 18 months, the coprimary endpoint of ischemic stroke or systemic embolism occurring after 7 days post-randomization was noninferior to long-term therapy with warfarin (event rate of 0.025 vs. 0.020, respectively). Importantly, late ischemic stroke events in the Watchman arm were suggested after 14 months (9) . Notably, the rate of hemorrhagic stroke in warfarintreated patients was nearly double the rate reported in other contemporary AF warfarin studies (8, 11, 12) . and may also possibly pay later (late thromboembolism). The jury is still out as we await clarity from long-term efficacy data.
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